Targeting EGFR in lung cancer: Lessons learned and future perspectives
CE Steuer, SS Ramalingam - Molecular aspects of medicine, 2015 - Elsevier
The development of individualized therapies has become the focus of current oncology
research. Precision medicine has demonstrated great potential for bringing safe and
effective drugs to those patients stricken with cancer, and is becoming a reality as more
oncogenic drivers of malignancy are discovered. The discovery of Epidermal Growth Factor
Receptor (EGFR) mutations as a driving mutation in non-small cell lung cancer (NSCLC)
and the subsequent success of the tyrosine kinase inhibitors (TKI) have led the way for …
research. Precision medicine has demonstrated great potential for bringing safe and
effective drugs to those patients stricken with cancer, and is becoming a reality as more
oncogenic drivers of malignancy are discovered. The discovery of Epidermal Growth Factor
Receptor (EGFR) mutations as a driving mutation in non-small cell lung cancer (NSCLC)
and the subsequent success of the tyrosine kinase inhibitors (TKI) have led the way for …
